相关实验视频

Updated: Jun 3, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

糖尿病病相关的动脉动脉功能障碍不是由平均动脉压及其决定因素调解的

Hon-Chun Hsu^1,2, Makabongwe S'kholiwe Mazibuko¹, Chanel Robinson¹

¹Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.

Journal of clinical medicine

|January 8, 2025

概括

糖尿病病会影响大动脉功能,而不影响血压. 虽然血压管理可以改善慢性病患者的大动脉功能,但当糖尿病病是唯一的原因时,它可能没有帮助.

科学领域:

心血管医学心血管医学
腎臟病學 (nephrology) 是一種醫學專業.
高血压研究高血压研究

背景情况:

糖尿病病 (DNP) 是糖尿病的一种严重并发症,经常导致慢性病 (CKD).
大动脉功能受损,表现为硬度增加和血液动力学变化,是CKD患者常见的并发症.
平均动脉压 (MAP),其决定因素和DNP相关的大动脉功能障碍之间的相互作用需要进一步阐明.

研究的目的:

研究糖尿病脏病 (DNP) 患者的平均动脉压 (MAP) 和其决定因素 (心脏输出,全身血管抵抗) 与大动脉功能受损之间的关联.
确定MAP及其决定因素是否调解DNP对大动脉功能的影响.
区分DNP与其他CKD病因对大动脉血液动力学的影响.

主要方法:

研究了115名慢性病 (CKD) 患者 (非透析和透析) 的多民族队列.
动脉功能的评估是使用 SpygmoCor 评估的六项措施,通过心声回声学确定中风体积.
患者数据包括CKD病因,心血管疾病史和血液动力学参数 (MAP,心脏输出,全身血管阻力).

主要成果:

糖尿病病 (DNP) 独立地与大动脉功能受损相关,不论是平均动脉压 (MAP) 或其决定因素.
高血压性脏病 (HNP) 与大动脉功能没有显著关系.
在整体CKD人群中,MAP及其决定因素与大动脉功能受损有关,但没有调解DNP特异性影响.

结论:

虽然平均动脉压 (MAP) 和其决定因素与一般CKD人群中的大动脉功能受损有关,但它们并不介于糖尿病病 (DNP) 特别引起的功能障碍.
降低血压的策略可以在CKD患者中改善大动脉功能.
这些发现表明,对于DNP诱导的大动脉功能障碍,可能需要除了血压控制之外的其他治疗点.

关键词:

大动脉的功能功能.心脏输出的心脏输出.糖尿病性脏病糖尿病脏病平均动脉压力是指动脉的压力.系统性血管阻力系统性血管阻力

更多相关视频

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats

Published on: February 8, 2022

Measurement of Pulse Propagation Velocity, Distensibility and Strain in an Abdominal Aortic Aneurysm Mouse Model

Measurement of Pulse Propagation Velocity, Distensibility and Strain in an Abdominal Aortic Aneurysm Mouse Model

Published on: February 23, 2020

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Hypertension and Regulation of Blood Pressure

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Action of Diuretics

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...